KR950702427A - 수정된 껍질알을 포함하는 조성물(Composition comprising fertilised shell eggs) - Google Patents

수정된 껍질알을 포함하는 조성물(Composition comprising fertilised shell eggs) Download PDF

Info

Publication number
KR950702427A
KR950702427A KR1019950700348A KR19950700348A KR950702427A KR 950702427 A KR950702427 A KR 950702427A KR 1019950700348 A KR1019950700348 A KR 1019950700348A KR 19950700348 A KR19950700348 A KR 19950700348A KR 950702427 A KR950702427 A KR 950702427A
Authority
KR
South Korea
Prior art keywords
composition
hatched
human
libido
dried
Prior art date
Application number
KR1019950700348A
Other languages
English (en)
Other versions
KR100277095B1 (ko
Inventor
에스켈란드 비요든
지엔 뎀스조 페더
Original Assignee
토아 그젠데비스텔, 잔 토마스 크젠들리에
드라이메드 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NO922988A external-priority patent/NO302335B1/no
Priority claimed from GB939314335A external-priority patent/GB9314335D0/en
Application filed by 토아 그젠데비스텔, 잔 토마스 크젠들리에, 드라이메드 에이에스 filed Critical 토아 그젠데비스텔, 잔 토마스 크젠들리에
Publication of KR950702427A publication Critical patent/KR950702427A/ko
Application granted granted Critical
Publication of KR100277095B1 publication Critical patent/KR100277095B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Insulating Materials (AREA)
  • Insulated Conductors (AREA)
  • Golf Clubs (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

예로 조류알, 특히 달걀인 수정된 부화 껍질알이 성적 능력 또는 리비도를 증진시키고 혈증 테스토스테론 수준을 상승시키는 작용을 하는 조성물을 만드는데 사용될 수 있다.

Description

수정된 껍질알을 포함하는 조성물(Composition comprising fertilised shell eggs)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1내지 제3도는 활성 작용제와 위약(placebo)에 시험기간에 걸쳐 VAS스코어로서 환자의 반응을 그래프로 나타낸다.

Claims (15)

  1. 임의적으로 하나 이상의 생리학적으로 허용가능한 담체 또는 부형제와 함께, 건조된 수정되고 부화된 껍질 알 노른자위 또는 그의 리비도 또는 테스토스테론 증진성분의 리비도 및/ 또는 테스토스테론 증진향을 포함하는 조성물.
  2. 제1항에 있어서, 냉동 건조된 조류알 또는 그의 상기 성분은 포함하는 조성물.
  3. 제2항에 있어서, 냉동 건조된 달걀 또는 그의 상기 성분을 포함하는 조성물.
  4. 제1항 내지 제3항중 어느 한 항에 있어서, 냉동 건조된 껍질 알 노른자위를 포함하는 조성물.
  5. 제1항 내지 제4항중 어느 한 항에 있어서, 상기 건조된 알이 배엽 내지 프로토배단계까지 부화된 알인 조성물.
  6. 제5항에 있어서, 상기 건조된 알이 약10일 동안 부화된 건조된 달걀인 조성물.
  7. 제1항 내지 제6항중 어느 한 항에 있어서, 70내지 80중량%의 건조된 알을 함유하는 단일 투여 형태인 조성물.
  8. 리비도를 증가시키기 위하여 사람 또는 비인간 포유동물 신체의 치료에 사용하기 위한 약제의 제조용 수정되고 부화된 껍질 알 노른자위의 용도용.
  9. 테스토스테론 수준을 향상시키기 위하여 사람 또는 비인간 포유동물 신체의 치료에 사용하기 위한 약제의 제조용 수정되고 부화된 껍질 알 노른자위의 용도.
  10. 수정되고 부화된 껍질 알 노른자위로 부터 유래된 치료제를 사람 또는 비인간 포유동물 체내에 투여하는 것을 포함하는 리비도를 증가시키기 위하여 또는 체내 테스토스테론 수준을 증진시키는 사람 또는 비인간 포유동물 신체의 치료방법.
  11. 제10항에 있어서, 상기 작용제가 경구적으로 투여되는 방법.
  12. 제10항에 있어서, 수정되고 부화된 껍질 알 내용물을 일일 1내지 50g(건조고체 기준)을 사람 체내에 투여하는 방법.
  13. 제12항에 있어서, 상기 내용물이 건조된 가루투성이 형태로 투여되는 방법.
  14. 배엽 내지 프로토단계까지 수정된 껍질 알을 부화시키고, 껍질 내용물, 또는 리비도 또는 테스토스테론 증진 활성을 가즌 그의 성분을 냉동건조시키는 것을 포함하는 성적 능력 또는 리비도 또는 테스토스테론 증진제의 제조방법.
  15. 제14항에 있어서, 약 10일 동안 수정된 달걀을 부화시키고, 그 내용물을 냉동건조시키며, 결과적인 생성물을 분말로 분쇄하고, 그 분말을 어떤 바람직한 생리학적으로 허용가능한 첨가제와 혼합하는 것을 포함하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950700348A 1992-07-29 1993-07-22 테스토스테론증강용조성물및그제조방법 KR100277095B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
NO922988A NO302335B1 (no) 1992-07-29 1992-07-29 Potensfremmende middel og fremstilling derav
NO922988 1992-07-29
NO07/922,130 1992-07-29
GB939314335A GB9314335D0 (en) 1993-07-08 1993-07-08 Composition
GB9314355.2 1993-07-08
GB9314335.2 1993-07-08
PCT/GB1993/001553 WO1994003192A1 (en) 1992-07-29 1993-07-22 Composition comprising fertilized shell eggs

Publications (2)

Publication Number Publication Date
KR950702427A true KR950702427A (ko) 1995-07-29
KR100277095B1 KR100277095B1 (ko) 2001-11-22

Family

ID=26303227

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950700348A KR100277095B1 (ko) 1992-07-29 1993-07-22 테스토스테론증강용조성물및그제조방법

Country Status (13)

Country Link
US (1) US5641517A (ko)
EP (1) EP0656781B1 (ko)
JP (1) JP3065353B2 (ko)
KR (1) KR100277095B1 (ko)
CN (1) CN1100545C (ko)
AT (1) ATE188609T1 (ko)
AU (1) AU4715093A (ko)
CA (1) CA2141197A1 (ko)
DE (1) DE69327585T2 (ko)
FI (1) FI950369A (ko)
IS (1) IS4057A (ko)
NZ (1) NZ254859A (ko)
WO (1) WO1994003192A1 (ko)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO303819B1 (no) * 1996-11-20 1998-09-07 Drymed As Anvendelse av t°rkede, fertiliserte h°nse-egg for fremstilling av anti-depressive midler
CA2439591C (en) * 2001-03-02 2008-01-29 Kalsec, Incorporated Labiatae herb extracts and hop extracts for extending the color life and inhibiting the growth of microorganisms in fresh meat, fish and poultry
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8142819B2 (en) * 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7666449B2 (en) * 2001-06-20 2010-02-23 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US8168234B2 (en) * 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
AU2008243262B2 (en) * 2001-06-20 2012-01-19 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US20040115290A1 (en) * 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
AU2003286549B2 (en) * 2002-10-21 2006-11-30 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
JP2007527407A (ja) * 2003-05-22 2007-09-27 メタプロテオミクス， エルエルシー 炎症を軽減するためおよび胃腸毒性の処置または予防のための抗炎症性薬学的組成物
CN1332646C (zh) * 2003-10-08 2007-08-22 张洪庭 一种治疗白发脱发排毒的洗发膏
EP1722635B1 (en) * 2004-02-23 2015-11-04 SSS Acquisition, LLC Feeds containing hop acids and uses thereof as supplements in animal feeds
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
MX2007005697A (es) * 2004-11-13 2007-10-08 Metaproteomics Llc Composiciones que exhiben la inhibicion de ciclooxigenasa-2.
NZ565782A (en) * 2005-08-09 2013-01-25 Metaproteomics Llc Combination of reduced isoalpha acid isohumulones and an acacia extract for the treatment of metabolic syndrome / syndrome X
EP1976552A4 (en) * 2005-12-09 2009-09-16 Metaproteomics Llc MODULATION OF PROTEIN KINASE WITH HOP AND ACACIA PRODUCTS
US20070275036A1 (en) 2006-05-18 2007-11-29 Celldyne Biopharma, Llc Avian follistatin product
US10835576B2 (en) * 2006-05-18 2020-11-17 Myos Rens Technology Inc. Method of obtaining effective amounts of avian follistatin
US20080051466A1 (en) * 2006-06-20 2008-02-28 Metaproteomics, Llc Isoalpha acid based protein kinase modulation cancer treatment
US20080033056A1 (en) * 2006-06-20 2008-02-07 Metaproteomics, Llc Xanthohumol based protein kinase modulation cancer treatment
JP2010505884A (ja) * 2006-10-12 2010-02-25 ユナイテッド パラゴン アソシエイツ インコーポレイテッド 受精卵の構成成分の調製方法
AU2008229110A1 (en) * 2007-03-19 2008-09-25 Metaproteomics, Llc Methods and compositions for promoting bone and joint health
US8241674B2 (en) * 2007-05-11 2012-08-14 Metaproteomics, Llc Methods and compositions for heavy metal detoxification
KR20100131969A (ko) * 2007-12-10 2010-12-16 메타프로테오믹스, 엘엘씨 암, 혈관신생 및 이와 관련된 염증 경로의 치환된 1,3-시클로펜타디온 다중-표적 단백질 키나아제 조절제
JP2011509262A (ja) 2008-01-11 2011-03-24 ユナイテッド パラゴン アソシエイツ インコーポレイテッド 受精卵分離物およびその使用
CN102066303A (zh) * 2008-04-02 2011-05-18 麦特普罗泰欧米克斯有限公司 取代1，3-环戊二酮减弱的内皮炎症以及内皮-单核细胞相互作用
GB2471827B (en) * 2009-05-11 2013-11-20 Med Eq As Treatment of stress
CN102397294A (zh) * 2010-09-07 2012-04-04 丁庆 提取自受精卵的组合物的壮阳和强精功效及其制作方法
RO128485A0 (ro) 2012-09-19 2013-06-28 Hipocrate 2002 Serv S.R.L. Compoziţie cu biodisponibilitate crescută a embrio-peptidelor administrate oral şi procedeu de obţinere
WO2015160262A1 (en) * 2014-04-16 2015-10-22 Amerikal Nutraceutical Corp Anti-aging composition
NL2023582B1 (en) * 2019-07-29 2021-02-22 Hatchtech Group Bv Use of chicken embryo meat

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1059230A (en) * 1964-12-08 1967-02-15 Arthur Samy Improvements in or relating to therapeutic products
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same

Also Published As

Publication number Publication date
US5641517A (en) 1997-06-24
JP3065353B2 (ja) 2000-07-17
FI950369A0 (fi) 1995-01-27
DE69327585D1 (de) 2000-02-17
IS4057A (is) 1994-01-30
ATE188609T1 (de) 2000-01-15
CA2141197A1 (en) 1994-02-17
JPH08502041A (ja) 1996-03-05
DE69327585T2 (de) 2000-08-10
KR100277095B1 (ko) 2001-11-22
FI950369A (fi) 1995-01-27
NZ254859A (en) 1997-02-24
AU4715093A (en) 1994-03-03
CN1098625A (zh) 1995-02-15
EP0656781A1 (en) 1995-06-14
EP0656781B1 (en) 2000-01-12
WO1994003192A1 (en) 1994-02-17
CN1100545C (zh) 2003-02-05

Similar Documents

Publication Publication Date Title
KR950702427A (ko) 수정된 껍질알을 포함하는 조성물(Composition comprising fertilised shell eggs)
KR900006885B1 (ko) 활성산소 억제 조성물 및 이의 제조방법
Pechter et al. Maggot therapy: the surgical metamorphosis
Basa et al. Review on medicinal value of honeybee products: Apitherapy
KR970003480B1 (ko) 약리학용 물질의 제조방법
Turner Counter-irritant and other medicinal uses of plants in Ranunculaceae by native peoples in British Columbia and neighbouring areas
CN105854021A (zh) 具有镇痛、抑菌双重效果的外用药物、制剂及其制备方法
RU2106088C1 (ru) Способ борьбы с блохами у домашних животных и средство для предотвращения поражения домашних животных блохами
JPH11514205A (ja) 有用な動物のストレス抵抗性および免疫の改善のための飼料もしくは飲料水の添加剤
JP2003155250A (ja) 関節痛を緩和する目的の健康食品
KR900007434A (ko) 시스타틴을 유효 성분으로하는 치료제
US5932236A (en) Pharmaceutical composition and methods for using it
RU2009136424A (ru) Композиция и способ лечения папилломавируса и саркоидов лошадей
US5648397A (en) Pharmaceutical composition and methods for using it
CN1057682C (zh) 一种治疗弓形虫病的药品
CN106614764A (zh) 含博落回及环丙氨嗪的灭蝇剂
ATE108063T1 (de) Heilmittel zur behandlung von toxoplasmose.
K'Eogh Zoologia Medicinalis Hibernica: Or, a Treatise of Birds, Beasts, Fishes, Reptiles, Or Insects, which are Commonly Known and Propagated in this Kingdom:... By John K'eogh,...
RU2220737C1 (ru) Лечебно-профилактическая композиция "остеомакс экстра" для улучшения функционального состояния опорно-двигательного аппарата
Boardman A Dictionary of the Veterinary Art: Containing All the Modern Improvements, and Including So Much of Comparative Anatomy, Physiology, Materia Medica, Chemistry, Pharmacy, Natural History, &c. &c. as is Connected with the Subject...
ATE107504T1 (de) Arzneimittel zur behandlung von kryptosporidiose.
RU2077319C1 (ru) Способ лечения псориаза
Duffin The stag as an historical source of materia medica
Branson 101 Amazing Uses for Garlic: Prevent Colds, Ease Seasickness, Repair Glass, and 98 More!
RU1808324C (ru) Способ профилактики и лечени казеинобезоарной болезни новорожденных гн т

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110819

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee